Dear Editor:

Hypoxemic respiratory insufficiency resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection might not be due to a “typical” acute respiratory distress syndrome (ARDS) [1]. As pulmonary compliance appears relatively preserved during the early stages of coronavirus disease 2019 (COVID-19), a role for right-to-left shunting due to pulmonary vasoplegia has been hypothesized, suggesting a possible therapeutic benefit from inhaled pulmonary vasodilators [1] including milrinone, nitric oxide, and cyclic prostanoids (e.g., iloprost). Inhaled iloprost improves oxygenation in non–COVID-19 ARDS with minimal adverse effects, and has mitigating effects on microvascular thrombosis, endothelial injury, and pulmonary inflammation [2] in animal models of ARDS, suggesting potential beneficial effects on mechanisms behind lung injury in COVID-19 [3]. We introduced inhaled iloprost as a rescue therapy for patients with refractory hypoxemia due to COVID-19. Systemic and pulmonary hemodynamics were monitored using a pulmonary artery catheter (PAC).

The local Institutional Review Board approved this study (IRB No. 2021_071). Informed consent for the treatment was obtained. We present retrospective data from a single center (December 2020–May 2021). We hypothesized that inhaled iloprost improves oxygenation by causing preferential pulmonary vasodilatation, which decreases the shunt fraction. We included data from mechanically ventilated patients with COVID-19, severe ARDS according to the Berlin criteria, and oxygenation index [OI = (mean airway pressure×FiO₂)/(PaO₂, resurss in mm Hg)] > 15 despite prone positioning, who were treated with iloprost, and in whom a PAC had been placed.

Iloprost (with a dose ranging 5–20 μg) was nebulized over 30 minutes and administered every 4 hours. The starting dose was 5 or 10 μg, which was increased on the basis of its clinical effects, up to a maximum of 20 μg. The effects on oxygenation were evaluated with arterial and mixed venous blood gas analyses. Samples were collected immediately before iloprost administration and then again at 30 and 60 minutes, and were repeated after any dose change. We calculated the right-to-left shunt fraction as follows:

\[ \frac{Q_S}{Q_T} \text{ (%)} = 100\% \times \frac{1 - CVO_2}{1 - CAO_2} \]

where \( Q_S/QT \) is the shunt fraction (percentage of cardiac output), and CAO₂ and CVO₂ are the arterial and mixed venous oxygen content, respectively.

Inhaled iloprost can improve oxygenation and shunt fraction in severe COVID-19

Christiaan M.C. Serbanescu-Kele Apor de Zalán¹, Norbert A. Foudraine¹, Jos L.M.L. Le Noble¹²

¹Department of Intensive Care, VieCuri Medical Center, Venlo; ²Department of Pharmacology and Toxicology, Maastricht University Medical Centre, Maastricht, Netherlands

Received: September 10, 2021
Revised: October 18, 2021
Accepted: December 16, 2021

Corresponding author
Christiaan M.C. Serbanescu-Kele
Apor de Zalán
Department of Intensive Care,
VieCuri Medical Center, Venlo, 5900
BX Venlo, Netherlands
Tel: +31-7-7320-6378
Fax: +31-7-7320-6145
E-mail: cserbanescu@viecuri.nl
Inhaled iloprost for severe COVID-19

Serbanescu-Kele Apor de Zalán CMC, et al.

Data are provided as median and interquartile range (IQR) or mean and standard deviation, and were compared using a paired t-test or Wilcoxon’s test, as appropriate (significance threshold, P<0.05).

In total, eight patients met the inclusion criteria. Their median age was 72.5 years (IQR, 67.3–73.8 years); six patients were male. The median positive end-expiratory pressure was 12 cm H₂O (IQR, 10–16 cm H₂O); the median OI was 17.8 (IQR, 14.9–20.7), and the median PaO₂ to FiO₂ (P/F) ratio was 75.8 (IQR, 69.6–97.0). Iloprost was started at a median of 23 days (IQR, 14–29.5 days) after onset of symptoms and 12 days (IQR, 9–20 days) after intubation. Up to three measurement sets were performed per patient, resulting in a total of 18 (Table 1). When only the first set of measurements were considered for each patient (n = 8), the median P/F ratio increased from 75.8 to 96.0 mm Hg (IQR, 69.6–97.0 vs. 78.4–144.4; P=0.012), the mean OI decreased from 17.3 to 14.4 (P=0.007; absolute and relative changes are shown in Figure 1A), and the mean Qs/Qt decreased from 43.6% to 37.5% (P=0.025) (Figure 1B). Considering all sets of measurements, the median P/F ratio increased from 93.5 to 105.0 mm Hg (IQR, 69.9–118.5 vs. 78.9–148.8; P<0.001), the mean OI decreased from 16.3 to 13.8 (P<0.001) (Supplementary Figure 1A), and the Qs/Qt decreased from 44.2% to 36.9% (P=0.001) (Supplementary Figure 1B). The relationships between changes in Qs/Qt and OI are shown in Figure 2. Two patients developed transient hemodynamic side effects: one patient had a drop in systemic vascular resistance, while the other experienced a decrease in left ventricular preload, evidenced by decreased capillary wedge pressure.

Our findings provide proof-of-concept that inhaled iloprost can improve oxygenation by decreasing the shunt fraction in mechanically ventilated patients with severe COVID-19 ARDS. To our knowledge, the effects of inhaled iloprost on shunt fraction in severe COVID-19 have not been previously described. These effects of iloprost on oxygenation reflect those described by Sonti et al. [4] after administration of inhaled epoprostenol. However, shunt fraction was not reported, and Tsareva’s study [5] included measurements at widely varying intervals. Tsareva et al. [5] found improved oxygenation after 5 days of treatment with iloprost, suggesting a possible disease-modifying effect. However, their patients were not critically ill, and shunt fraction was not described.

Interestingly, right-to-left shunt fraction at baseline varied widely (19%–70%), possibly reflecting different disease phenotypes in COVID-19. Furthermore, although most patients showed improved oxygenation after administration of iloprost, some had only a relatively short lived response, advocating the use of more frequent or continuous nebulization.

We used inhaled iloprost exclusively as a rescue therapy in patients in whom other interventions failed, which might have led us to include only the sickest patients. In such patients, consolidative and even fibrotic changes might have shown dominance over the vasculopathy that is thought to dominate hypoxemia in early COVID-19 (i.e., our patients might have already been in the H-stage, as proposed by Gattinoni et al. [1], wherein progressive parenchymal damage results in low compliance and a lesser role of vasoplegia).

From a pathophysiologic point of view, inhaled pulmonary vasodilators should have maximum effect during the L-stage, in which hypoxemia is thought to result primarily from ventilation/perfusion mismatch. Iloprost might have disease-modifying effects, by mediating platelet activation, endothelial damage, and pulmonary inflammation.

The retrospective nature of our study, its relatively small sample size, and the heterogenous patient population that

| Patient | Dose (μg) | Measurement |
|---------|-----------|-------------|
| 1       | 5, 10     | 2           |
| 2       | 10, 20    | 1           | First dose (10 μg) given before placement of PAC because of acute and severe hypoxaemia; measurement performed around second dose (20 μg) |
| 3       | 5, 10     | 2           |
| 4       | 10        | 3           | This patient had been in prone position for 13 days and desaturated upon multiple trials supine positioning. To allow for supine positioning, we started iloprost despite an initial OI of up to 10. |
| 5       | 20        | 2           | Initial dose of 20 μg because of acute and severe hypoxaemia |
| 6       | 10, 20    | 3           |
| 7       | 5         | 2           |
| 8       | 10, 20    | 2           |

PAC: pulmonary artery catheter; OI: oxygenation index.
received unequal doses in different phases of the disease preclude us from drawing conclusions about the magnitude of the effects of iloprost.

Future studies should aim to determine the category of COVID-19 patients that responds best to inhaled pulmonary vasodilators. In addition, measuring pulmonary hemodynamic parameters might contribute to further understanding of COVID-19 pathophysiology.

In conclusion, we found that inhaled iloprost can improve oxygenation in severe COVID-19 by decreasing shunt fraction.

**Figure 1.** (A) The left panel depicts absolute changes in oxygenation index (OI), and the right panel shows relative changes in OI after iloprost administration in eight patients with severe coronavirus disease 2019 (COVID-19). A similar figure, including all measurements obtained, is presented in Supplementary Figure 1A. (B) The left panel depicts absolute changes and the right panel shows relative changes in shunt fraction (Qs/Qt) after iloprost administration in eight patients with severe COVID-19. A similar figure that includes all measurements obtained is shown in Supplementary Figure 1B. (A, B) Only measurements obtained around the first dose of iloprost received by each patient were included. The X axis shows the timepoints at which measurements were performed.
Figure 2. The relationship between changes in oxygenation index (OI) and shunt fraction (Qs/Qt) after iloprost administration in 11 measurements obtained in eight patients with severe coronavirus disease 2019 (COVID-19). X-axis and Y-axis include the first available measurement after administration of iloprost, expressed relative to the values obtained at baseline (which were set to 1.0).

At baseline, shunt fraction varied widely, suggesting the existence of different mechanisms behind hypoxemia in severe COVID-19. Measuring the Qs/Qt should improve our understanding of refractory hypoxemia induced by SARS-CoV-2 and help tailor therapy for individual patients.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

We are grateful to our intensive care unit nurses, physicians and other staff. Without their help and expertise, the present study would not have been possible. We are specifically grateful for the contributions of Dr. O. Thomas in drafting the treatment protocol.

ORCID

Christiaan M.C. Serbanescu-Kele Apor de Zalán
https://orcid.org/0000-0003-2184-810X
Norbert A. Foudraine
https://orcid.org/0000-0003-1353-4434
Jos L.M.L. Le Noble
https://orcid.org/0000-0003-3367-6333

AUTHOR CONTRIBUTIONS

Conceptualization: all authors. Data curation: CMCSAZ. Formal analysis: CMCSAZ. Methodology: all authors. Project administration: JLM, CMCSAZ. Visualization: CMCSAZ. Writing—original draft: CMCSAZ, JIN. Writing—review & editing: all authors.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found via https://doi.org/10.4266/acc.2021.01263.

REFERENCES

1. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;201:1299-300.
2. Riva CM, Morganroth ML, Ljungman AG, Schoeneich SO, Marks RM, Todd RF 3rd, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol 1990;3:301-9.
3. Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, et al. Thrombocytopenia and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol 2021;18:194-209.
4. Sonti R, Pike CW, Cobb N. Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19. J Intensive Care Med 2021;36:327-33.
5. Tsareva NA, Avdeev SN, Kosanovic D, Schermuly RT, Trushenko NV, Nekludova GV. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care 2021;25:258.